Raloxifene Hydrochloride
Product Images NDC 68071-2412

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Raloxifene Hydrochloride (NDC 68071-2412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2412 3)

Pdp (68071 2412 3)
The packaging label for Raloxifene Hydrochloride 60mg tablets by NuCare Pharmaceuticals, Inc. The label indicates a package containing 30 tablets, with directions to take one tablet every 12 hours. The label includes NDC 68071-2412-3, a warning to keep out of reach of children, storage instructions at controlled temperature 68-77°F, and a note to see the manufacturer's label for a full list of ingredients. Additional manufacturer and serial information is also present.*
FDA Label Image

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-structure01.jpg)

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-structure01.jpg)
Chemical structure of Raloxifene Hydrochloride, showing its molecular arrangement including aromatic rings, hydroxyl groups, sulfur atom, and a piperidine moiety with a chloride ion.*
FDA Label Image

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-figure01.JPG)

\\client\x$\products\raloxifene Hydrochloride Tabs Anda 078193\submissions\2016-03-18 Cbe-0 (AJK\Working\INSERT\Image File\raloxifene-figure01.JPG)
Two line graphs show the total hip mean percentage change from baseline over 24 months after randomization for raloxifene hydrochloride, placebo, and conjugated estrogens (CE). The graphs compare data from different studies, illustrating the percentage change by months with raloxifene hydrochloride generally showing a positive trend compared to placebo and CE in the second graph.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.